Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of BAX 855 in young children with severe hemophilia A
2015-002136-40Phase 3
- Sponsor
- Baxalta
- Start
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of rurioctocog alfa pegol in hemophilia A, sponsored by Baxalta.
02
Drugs
rurioctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2015-002136-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002136-40.